Several studies to date have focused on the role of ET-1 and functional autoantibodies—particularly anti-ETAR and anti-AT1R—as biomarkers of CTD-PAH, and their serum levels are occasionally measured for research and clinical purposes in referral centres [51]. This evidence concerns the gene AGTR1 and pulmonary arterial hypertension.